Pfizer has developed a new vaccine targeting Lyme disease, which impacts nearly half a million Americans annually.
While the vaccine has shown some efficacy in trials, it did not meet a significant statistical hurdle necessary for broader approval.
This outcome may influence future vaccine development strategies and public health responses to Lyme disease.